Cellarity news and updates

Every material change AI Health Index has tracked at Cellarity: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms
Impact
Type
1 entry
Showing changes for Cellarity only.Show the full log

October 2026

C
Cellarity
Oct 29, 2026
HighVerified
Acquisition / corporate

Flagship Pioneering formed Etcelera, a new company that takes the Cellarity AI drug discovery platform forward alongside the platforms of Etiome and Empress Therapeutics. Cellarity itself continues only as a standalone clinical company built around its sickle cell candidate CLY-124, with the platform no longer part of it.

Our read

Buyers and partners evaluating the Cellarity platform now deal with Etcelera, so the vendor listed in the index no longer owns the AI platform the index grades.

Related axis: AI CentralityVendor announcementView source

What has changed at Cellarity recently?

The most recent change AI Health Index logged at Cellarity is dated Oct 29, 2026. Flagship Pioneering formed Etcelera, a new company that takes the Cellarity AI drug discovery platform forward alongside the platforms of Etiome and Empress Therapeutics.